Future Directions
1. Expand and validate gene expression signatures in entire
low grade lymphoma cohort
2. Translate signatures back to laboratory for functional
studies
3. Expand collaboration to other centers/institutes
4. Adapt the proposed workflow to other lymphoma subtypes